Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

The Liverpool School of Tropical Medicine

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

Valneva shares positive phase 3 results for chikungunya vaccine in adolescents

The company has submitted label extension applications for Ixchiq in this age group

- PMLiVE

GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults

The company said it will now progress the programme into late-stage clinical development

- PMLiVE

LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

The rare neurodegenerative disease affects one in every 300 people in the UK

- PMLiVE

UKHSA publishes five-year strategy to detect risk-posing pathogens in UK

The strategy will help to improve the UK's response to infectious disease threats

- PMLiVE

LifeArc launches £5m motor neurone disease drug repurposing programme

Research teams will be eligible to receive up to £750,000 per project through the programme

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

New UK research institute launched for motor neurone disease

The research institute will bring together MND labs, clinical centres and researchers

- PMLiVE

WHO releases 13 interventions to help address antimicrobial resistance

The organisation has declared AMR as one of the top ten threats to global public health

- PMLiVE

GSK survey results highlight meningitis knowledge gaps among parents

More than 90% of parents did not know all three common symptoms of the infection

- PMLiVE

Medscape Education’s Large Presence at IDWeek 2023

Medscape are powering education and disease state awareness in infectious diseases at #IDWeek 2023

Medscape Education

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links